Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Early Phase 1
1(20.0%)
5Total
Phase 1(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03546335Phase 1Suspended

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Role: lead

NCT05851365Early Phase 1Active Not Recruiting

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

Role: lead

NCT05245006Phase 1Active Not Recruiting

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Role: lead

NCT05892393Phase 1Recruiting

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Role: lead

NCT06894745Phase 1Recruiting

PET [89Zr]DFO-starPEG in Solid Tumors

Role: lead

All 5 trials loaded